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Background: GSK2190915 is a high affinity 5-lipoxygenase-activating protein inhibitor being developed for the
treatment of asthma. The objective of this study was to evaluate GSK2190915 efficacy, dose–response and safety in
subjects with persistent asthma treated with short-acting beta2-agonists (SABAs) only.
Methods: Eight-week multicentre, randomised, double-blind, double-dummy, stratified (by age and smoking
status), parallel-group, placebo-controlled study in subjects aged ≥12 years with a forced expiratory volume in
1 second (FEV1) of 50–85% predicted. Subjects (n = 700) were randomised to receive once-daily (QD) oral
GSK2190915 (10–300 mg), twice-daily inhaled fluticasone propionate 100 μg, oral montelukast 10 mg QD or
placebo. The primary endpoint was mean change from baseline (randomisation) in trough (morning pre-dose and
pre-rescue bronchodilator) FEV1 at the end of the 8-week treatment period. Secondary endpoints included morning
and evening peak expiratory flow, symptom-free days and nights, rescue-free days and nights, day and night-time
symptom scores, day and night-time rescue medication use, withdrawals due to lack of efficacy, Asthma Control
Questionnaire and Asthma Quality of Life Questionnaire scores.
Results: For the primary endpoint, there was no statistically significant difference between any dose of GSK2190915
QD and placebo. However, repeated measures sensitivity analysis demonstrated nominal statistical significance for
GSK2190915 30 mg QD compared with placebo (mean difference: 0.115 L [95% confidence interval: 0.00, 0.23],
p = 0.044); no nominally statistically significant differences were observed with any of the other doses. For the
secondary endpoints, decreases were observed in day-time symptom scores and day-time SABA use for
GSK2190915 30 mg QD versus placebo (p≤ 0.05). No dose–response relationship was observed for the primary and
secondary endpoints across the GSK2190915 dose range studied; the 10 mg dose appeared to be sub-optimal.
GSK2190915 was associated with a dose-dependent reduction in urinary leukotriene E4. The profile and incidence of
adverse events were similar between treatment groups.
Conclusion: Efficacy was demonstrated for GSK2190915 30 mg compared with placebo in day-time symptom
scores and day-time SABA use. No additional improvement on efficacy endpoints was gained by administration of
GSK2190915 doses greater than 30 mg. GSK2190915 was well-tolerated. These results may support further studies
with GSK2190915 30 mg.
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Leukotrienes (LTs) are produced by mast cells, eosino-
phils, macrophages and neutrophils in response to aller-
gic or inflammatory stimuli [1-3]. They are products of
the 5-lipoxygenase (5-LO) pathway of arachidonic acid
metabolism and their synthesis is initiated by 5-LO in
concert with 5-lipoxygenase-activating protein (FLAP).
This part of the pathway divides into two branches: one
leading to production of LTB4 and the other to the pro-
duction of the cysteinyl LTs (cysLTs) LTC4, LTD4 and
LTE4, so-called because they contain the amino acid
cysteine conjugated to their lipid backbone. The central
role of LTs in asthma pathogenesis is well-established as
they function as potent mediators of inflammation and
airway constriction [4-7]. Concentrations of the products
of the 5-LO pathway are increased in patients with
asthma of all severities despite treatment with cortico-
steroids [8-10], the cornerstone anti-inflammatory the-
rapy in asthma.
Leukotriene B4 is a potent chemoattractant of neutro-
phils [11]. Irrespective of therapy with corticosteroids,
LTB4 concentrations were increased in the bronchoalveo-
lar fluid, sputum and tissue of patients with severe asthma
compared with non-asthmatic control subjects and pa-
tients with mild-moderate asthma [10,12]. Neutrophil
numbers have been shown to increase in patients with
severe asthma compared with milder asthma phenotypes,
and neutrophilic inflammation is resistant to the effects
of corticosteroids [9,12,13]. The cysLTs are potent
constrictors of airway smooth muscle, they increase
vascular permeability and serve as chemoattractants for
eosinophils [4-6]. Cysteinyl LTs are directly involved in
bronchoconstriction, airway oedema and mucus secretion,
characteristic of the asthmatic phenotype [14]. Inhibition
of cysLTs by the administration of the cysLT receptor
antagonist montelukast elicits bronchodilatory effects and
significantly reduces eosinophil numbers in the peripheral
blood and induced sputum of patients with asthma [15].
In addition, administration of the 5-LO inhibitor zileuton
to patients with severe asthma led to improvements in
lung function [16]. These observations indicate that
inhibition of the production of LTs via the two branches
of the 5-LO pathway could confer beneficial effects
on patients with persistent asthma.
GSK2190915 is a high affinity FLAP inhibitor that
attenuates the production of LTs through inhibition of
the first step of the 5-LO pathway. In vitro and in vivo
studies demonstrated that GSK2190915 reproducibly
inhibited the production of both LTB4 and cysLTs [17].
In healthy subjects, GSK2190915 was well-tolerated with
a systemic exposure that increased in a dose-related
manner [18]. GSK2190915 also demonstrated dose-
dependent inhibition of blood LTB4 production and of
urinary excretion of the cysLT, LTE4 [18]. The primaryobjective of the current study was to evaluate the efficacy,
dose–response, safety and tolerability of GSK2190915 ad-
ministered once-daily (QD) over an 8-week period in ado-
lescents and adults with persistent uncontrolled asthma
receiving a short-acting beta2-agonist (SABA). The sec-
ondary objective of this study was to explore the efficacy
of GSK2190915 against established asthma treatments,
namely montelukast and the inhaled corticosteroid (ICS)
fluticasone propionate (FP).Methods
Subjects
Subjects aged 12 years or older were eligible for enrol-
ment if they had a diagnosis of asthma (as defined by
the National Institutes of Health [19]) with a best (the
highest of three technically acceptable measurements)
pre-bronchodilator forced expiratory volume in 1 second
(FEV1) of 50–85% of the predicted normal value, and re-
versibility of at least 12% and 200 mL within 30 minutes
after inhaled salbutamol/albuterol. The original protocol
also allowed males to be recruited to the study. However,
the protocol was amended to include only females after
findings of testicular toxicity in rats at high exposures of
GSK2190915 following 6-month dosing were reported
during the conduct of the study. Former and current
smokers, with a smoking history of ≤10 pack years,
were required to demonstrate a post-salbutamol/albute-
rol FEV1/forced vital capacity ratio of >0.70 to exclude
subjects with fixed airways. Eligible subjects were re-
quired to have been taking a SABA for at least 3 months
before screening. They were also required to be able to
replace their SABA with salbutamol/albuterol to be used
as rescue medication during the run-in and treatment
periods. Other permitted medications included stable-
dose immunotherapy, intranasal corticosteroids and short
and long-acting antihistamines.
Exclusion criteria at screening included a history of
life-threatening asthma (defined as an asthmatic episode
that had required intubation and/or was associated with
hypercapnoea, respiratory arrest or hypoxic seizures with-
in the last 5 years), an asthma exacerbation requiring oral
corticosteroids in the 3 months prior to screening or hos-
pitalisation for asthma in the previous 6 months, an unre-
solved infection in the past 4 weeks leading to a change in
asthma management or that affected the subject’s asthma
status or ability to participate in the study, use of ICSs
in the past 6 weeks or of systemic, oral or depot corti-
costeroids in the past 12 weeks. Non-smoking subjects
were not permitted to have used tobacco products within
6 months of screening. Subjects were also excluded if they
had received statins or other organic anion transport
protein 1B1 substrates within 4 weeks of screening or
had any adverse reaction including immediate or delayed
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drug, intranasal, inhaled or systemic corticosteroid.
Study design
This was a Phase IIb, multicentre, randomised, double-
blind, double-dummy, parallel-group, placebo-controlled
study that was conducted from January 2010 to October
2011 at 89 sites in six countries (GlaxoSmithKline proto-
col: LPA112186; Clinicaltrials.gov registration number:
NCT01147744). All subjects provided signed informed
consent prior to screening. Local Ethics Review Commit-
tees provided approval for the study, which was conduc-
ted in accordance with Good Clinical Practice, applicable
country-specific requirements and the guiding principles
of the Declaration of Helsinki (2008).
Eligible subjects completed a 2-week pre-treatment
run-in period during which they were required to attend
the clinical unit for assessment of their adherence with
an electronic daily diary (eDiary, AM3 device by ERT,
Bavaria, Germany). At the end of the study run-in
period, subjects were eligible to enter the treatment
period if they had a morning pre-dose FEV1 between
50% and 85% of their predicted normal and had either
any combination of the daily asthma symptom scores
(day-time plus night-time) of ≥1, or used salbutamol/al-
buterol on at least 4 days of the last 7 consecutive days
of the run-in period.
Subjects were randomised to receive GSK2190915 ta-
blets (10 mg, 30 mg, 100 mg, 300 mg) QD (morning),
FP 100 μg twice-daily (BID; morning and evening) via a
Diskus™/Accuhaler™ (GlaxoSmithKline, Ware, UK) and
montelukast 10 mg capsules QD (evening). A double
dummy design was used to ensure blinding to treatment
(see Additional file 1). Subjects received treatment on an
out-patient basis for 8 weeks. Subjects aged 12–14 years
were not randomised to the montelukast arm as the
10 mg dose is not licensed for this age group. Randomi-
sation was stratified according to subject age and smo-
king status. Follow-up took place 1 week after completion
of the treatment period. Following their withdrawal, all
male subjects were offered a clinical assessment.
Subjects were withdrawn from study medication due
to ‘lack of efficacy’ if they changed their asthma medica-
tion, had an asthma exacerbation (defined as worsening
asthma requiring any treatment other than rescue sal-
butamol/albuterol) or had signs of asthma instability
(defined as a fall in clinic FEV1 to <80% of value at ran-
domisation, peak expiratory flow [PEF] < 80% of the
mean run-in value on more than 3 days between con-
secutive visits or use of salbutamol/albuterol ≥12 inhala-
tions/day on more than 2 days between consecutive
visits).
Adherence to treatment was assessed from Week 4
until Week 8 (or early withdrawal) by counting returnedtablets, capsules and reviewing the dosing counter on
the Diskus/Accuhaler. Allocation to treatment group
was determined according to a computer generated sche-
dule; numbered containers were used to implement al-
location. Neither the subject nor the investigator knew
which study medication the subject was receiving.Efficacy assessments
Assessments of efficacy were based on measures of spi-
rometry, including trough FEV1 (pre-bronchodilator and
pre-dose); parameters recorded in the daily diary inclu-
ding symptoms, use of rescue medication and daily PEF;
questionnaires including Asthma Control Questionnaire
(ACQ)-6 and the Asthma Quality of Life Questionnaire
(AQLQ) (+12).
The primary endpoint of the study was mean change
from baseline (randomisation) in trough (morning pre-
dose and pre-rescue bronchodilator) FEV1 at the end of
the 8-week treatment period. Changes in FEV1 at weeks
1, 2, 4 and 6 were also assessed. Efficacy measures for
secondary endpoints recorded by the patients using the
daily diary were: mean change from baseline in daily
trough (pre-dose and pre-rescue bronchodilator) mor-
ning and evening PEF averaged over the 8-week treat-
ment period; mean change from baseline in the
percentage of symptom-free days and nights and rescue-
free days and nights; mean change from baseline in day
and night-time symptom scores; mean change from
baseline in day and night-time rescue salbutamol/albute-
rol use; withdrawals due to lack of efficacy and mean
change from baseline in ACQ and AQLQ scores. In
addition, other endpoints were assessed: symptom-free
24-hour periods, rescue-free 24-hour periods, 24-hour
period symptom scores and 24-hour SABA use.
All post-randomisation FEV1 measurements were ta-
ken within 1 hour of the time FEV1 was measured at
randomisation. Before attending the clinical unit for lung
function assessments, subjects had to withhold their res-
cue medication for at least 6 hours. At weeks 1, 2, 4, 6
and 8, FEV1 was measured approximately 24 hours post-
morning dose and approximately 12 hours post-evening
dose.Pharmacokinetic/pharmacodynamic assessments
Blood samples for pharmacokinetic analysis were collec-
ted at pre-dose on weeks 0, 2 and 4. Post-dose samples
were collected on weeks 1 and 8 within the following
time windows: first sample: 0.5–2 hours; second sample:
2–5 hours. Plasma samples from subjects who received
only GSK2190915 were analysed using a validated ana-
lytical method based on protein precipitation followed
by high performance liquid chromatography with tan-
dem mass spectrometry analysis. The lower limit of
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higher limit of quantification was 5000 ng/mL.
Three spot urine samples were collected at Week 0
and pre-dose on weeks 1 and 8 to determine mean
change from baseline in urinary LTE4. Urine samples
were analysed for LTE4 using a validated analytical me-
thod based on solid-phase extraction followed by high
performance liquid chromatography with tandem mass
spectrometric detection. The lower limit of quantifica-
tion for LTE4 was 5 pg/mL and the higher limit of quan-
tification was 1000 pg/mL.
Safety and tolerability measurements
Safety and tolerability were assessed by monitoring ad-
verse events during the treatment period until follow-up,
and serious adverse events from screening to follow-up.
Adverse events were coded using the Medical Dictionary
for Regulatory Activities (MedDRA). Asthma exacerba-
tions were recorded. Assessments of liver function, stan-
dard laboratory parameters, vital signs (pulse rate and
systolic and diastolic blood pressure) and 12-lead elec-
trocardiograms (ECGs) were also performed.
Statistical analysis
The primary hypothesis of the study was that FEV1
in the GSK2190915 groups would demonstrate a signifi-
cant increase at the end of the 8-week treatment period
compared with that in the placebo group. Assuming a
between-subject common standard deviation in FEV1 of
415 mL, it was estimated that it would be necessary to
recruit 630 subjects (90 per group) to provide 89% power
to detect a difference (two-sided 5% level) of 200 mL in
pairwise comparisons between any GSK2190915 dose
group and placebo.
A sequential testing procedure was followed to ac-
count for multiplicity from multiple pairwise compari-
sons: statistical comparison of the highest GSK2190915
dose with placebo was performed first and subsequent
comparisons at lower doses continued in a sequential
manner. A 5% level of statistical significance was claimed
only if the preceding comparison was significant at the
5% level. Any other test results were not adjusted for
multiplicity and any p-value ≤0.05 from those testing re-
sults was interpreted as nominally significant. Primary
efficacy analysis was performed using analysis of covari-
ance (ANCOVA) with a last observation carried forward
approach used to impute missing data; repeat measures
model was also performed for sensitivity analysis.
Secondary efficacy analysis was performed using
ANCOVA, except for the comparison between each
treatment group and placebo for the number of with-
drawals due to lack of efficacy in which a Fisher’s Exact
test was used. No multiplicity adjustments were made on
the secondary efficacy endpoints. Any p value ≤0.05 wasidentified as nominally significant. The comparisons
between active treatments were only for exploratory
purposes. Population pharmacokinetic analysis of sparse
GSK2190915 plasma concentration-time data was per-
formed using non-linear mixed effects modelling as was
the population pharmacokinetic-pharmacodynamic ana-
lysis to assess the plasma GSK2190915 concentration
versus urinary LTE4 relationship. Non-quantifiable phar-
macokinetic and pharmacodynamic data were treated as
missing for the population analysis. No formal statistical
analysis was performed on safety data. For all endpoints,
data are reported for subjects who received at least one
dose of study medication.Results
Subjects
Of 1245 subjects screened, 700 were randomised and
548 completed the study (Figure 1). One hundred and
thirteen (16%) subjects, including 56 males, were ran-
domised under the original protocol. However, after the
protocol was amended to withdraw males and include
females only, an additional 587 (84%) female subjects
were subsequently recruited. One hundred and fifty-two
(22%) subjects withdrew from the study and the most
frequent reasons for withdrawal were: lack of efficacy
(70 subjects), decision to withdraw all male subjects
(33 subjects) and withdrawal of consent (25 subjects).
The numbers of subjects in each group withdrawing
from the study were similar. Demographic and baseline
subject characteristics were well-matched across treat-
ment groups (Table 1).Efficacy
At the end of the 8-week treatment period, there was no
statistically significant difference between any dose of
GSK2190915 QD and placebo for mean change from
baseline in trough (morning pre-dose and pre-rescue
bronchodilator) FEV1 (Figure 2). Similar results were
obtained for montelukast 10 mg QD compared with pla-
cebo. However, mean difference in change from baseline
between FP 100 μg BID and placebo achieved nominal
statistical significance (Figure 2). The repeated measures
sensitivity analysis of change from baseline in trough
FEV1 indicated an overall increase for all doses of
GSK2190915 (Figure 3) with the greatest increase ob-
served for FP 100 μg BID. With the repeated measures
analysis, treatment differences (active minus placebo)
achieved nominal statistical significance for GSK2190915
30 mg QD at Week 8 (least squares [LS] mean dif-
ference: 0.115 L [95% confidence interval, CI: 0.00, 0.23],
p = 0.044). For FP 100 μg BID, nominal statistical signifi-
cance (active minus placebo) was achieved at all time-
points (Weeks 1 to 8).
Figure 1 CONSORT diagram. Subject flow through study. FP = fluticasone propionate.
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dose of GSK2190915 versus placebo in the secondary end-
points of morning and evening PEF, symptom-free days
and nights, rescue-free days and nights, night-time symp-
tom scores and night-time SABA use (Additional file 2);
similar results were observed for montelukast 10 mg QD
versus placebo. However, there were nominally statistically
significant differences for FP 100 μg versus placebo for
symptom-free days and rescue-free days. Nominally sta-
tistically significant reductions were observed for com-
parisons between GSK2190915 30 mg QD and placebo for
the secondary endpoints of day-time symptom scores and
day-time SABA use (Additional file 2). Comparisons be-
tween montelukast 10 mg QD or FP 100 μg and placebo
showed a nominally statistically significant decrease for
day-time SABA use (Additional file 2). Total scores for
ACQ and total and domain scores for AQLQ were similar
for placebo, GSK2190915 (any dose) and montelukast
10 mg QD whilst a nominally statistically significant
decrease was observed for FP 100 μg versus placebo
(Additional file 2). The percentage of symptom-free
24-hour periods, rescue-free 24-hour periods and 24-
hour period symptom scores was similar for placebo,GSK2190915 (any dose) and montelukast 10 QD. How-
ever, the percentage of symptom-free 24-hour periods and
rescue-free 24-hour periods was nominally statistically sig-
nificantly reduced for FP 100 μg compared with placebo.
There were nominally statistically significant decreases for
GSK2190915 30 mg QD, montelukast 10 mg QD and FP
100 μg versus placebo for 24-hour SABA use. Notable im-
provements were observed in the placebo group for all ef-
ficacy endpoints.
Pharmacokinetics/pharmacodynamics results
Plasma GSK2190915 levels increased in an approximately
dose proportional manner. Geometric mean (inter-subject
variability [%CV]) trough plasma GSK2190915 concentra-
tions were 29 (73) ng/mL following GSK2190915 10 mg
QD, 66 (84) ng/mL following GSK2190915 30 mg QD,
157 (110) ng/mL following GSK2190915 100 mg QD, and
370 (111) ng/mL following GSK2190915 300 mg QD. The
sparse plasma GSK2190915 concentration-time data were
described by a one-compartment population pharmacoki-
netic model. Population mean (%CV) oral clearance was
16 (76) L/hour and apparent volume of distribution was
162 (99) L. Model derived geometric mean (%CV) area













N = 100 N = 99 N = 100 N = 100 N = 101 N = 103 N = 97
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age in years; Mean [range] 42.3 [12–71] 40.0 [12–75] 43.1 [12–73] 42.2 [12–69] 42.2 [12–69] 41.5 [12–74] 44.3 [15–78]
BMI in kg/m2; Mean [range] 27.5 [16–47] 27.5 [17–49] 26.8 [16–43] 27.8 [16–52] 26.9 [19–63] 27.0 [15–55] 27.1 [18–54]
Sex; n (%)
Female 88 (88) 91 (92) 94 (94) 92 (92) 93 (92) 97 (94) 89 (92)
Male 12 (12) 8 (8) 6 (6) 8 (8) 8 (8) 6 (6) 8 (8)
Race; n (%)
White 82 (82) 74 (75) 78 (78) 78 (78) 78 (77) 83 (81) 76 (78)
Black 6 (6) 12 (12) 10 (10) 9 (9) 9 (9) 7 (7) 9 (9)
Other 12 (12) 13 (13) 12 (12) 13 (13) 14 (14) 13 (13) 12 (12)
Smoking-history; n (%)
Never smoked 78 (78) 85 (86) 83 (83) 77 (77) 86 (85) 86 (83) 78 (80)
Current smoker 12 (12) 9 (9) 10 (10) 11 (11) 10 (10) 13 (13) 13 (13)
Former smoker 10 (10) 5 (5) 7 (7) 12 (12) 5 (5) 4 (4) 6 (6)
FEV1 in L; Mean [range] 2.0 [1.2–3.7] 2.0 [1.0–3.3] 1.9 [1.1–2.8] 2.0 [1.0–3.5] 2.0 [1.1–3.4] 2.0 [1.0–4.0] 2.0 [0.9–3.5]
% predicted; Mean [range] 68.7 [51–87] 67.7 [50–96] 66.1 [50–85] 67.8 [51–85] 66.8 [51–85] 66.6 [37–85] 69.2 [50–85]
Atopy, n% 22 (22) 30 (30) 31 (31) 31 (31) 35 (35) 35 (34) 34 (35)
QD Once-daily, FP Fluticasone propionate, BID Twice-daily, BMI Body mass index, FEV1 Forced expiratory volume in 1 second.
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steady-state was 761 (72) ng.hour/mL for GSK2190915
10 mg QD, 2197 (75) ng.hour/mL for GSK2190915 30 mg
QD, 6390 (64) ng.hour/mL for GSK2190915 100 mg QD
and 19315 (88) ng.hour/mL for GSK2190915 300 mg QD.
Exposure to GSK2190915 was associated with a de-
crease in urinary LTE4 levels (Figure 4). The plasma
GSK2190915 concentration versus urinary LTE4 rela-
tionship was described by an inhibitory Emax model. The
GSK2190915 plasma concentration associated with 50%
of maximum (100%) urinary LTE4 inhibition was 33
(113) ng/mL, which equates to a GSK2190915 trough
plasma concentration achieved with a dose of 10 mg.
Safety and tolerability
The incidence of adverse events was generally similar be-
tween treatment groups (Table 2). The most frequently
reported adverse events were headache and nasopharyn-
gitis. Four subjects experienced serious adverse events:
dislocated joint (n = 1, GSK2190915 10 mg QD), cranial
neuritis (n = 1, GSK2190915 30 mg QD), small intestine
obstruction (n = 1, GSK2190915 100 mg QD) and injured
cartilage (n = 1, FP 100 μg BID); none of the events was
considered related to study drug by the investigators and
all resolved except the cranial neuritis, which led to sub-
ject withdrawal from the study. Eleven subjects were
discontinued from the study as a consequence of an ad-
verse event. Five of these were considered drug-related:decreased appetite and nausea (n = 1, placebo), dyspnoea
(n = 1, GSK2190915 10 mg QD), extrasystoles and diar-
rhoea (n = 2, GSK2190915 300 mg QD) and drug eruption
(n = 1, montelukast 10 mg QD). No drug-related adverse
events were reported by more than one subject in any
treatment group. Fifteen subjects experienced asthma exa-
cerbations across all treatment groups except FP 100 μg
BID; all episodes were treated with corticosteroids and all
exacerbations resolved. One subject became pregnant
during the run-in period and was withdrawn before
randomisation. No abnormalities in male reproductive
health were detected in the follow-up data from the male
subjects who participated in the study and underwent
follow-up testing. There were no significant or clinically
meaningful differences between active treatments and
placebo in blood chemistry (including liver function),
haematology, urinalysis, vital signs and ECG parameters.
Discussion
Administration of GSK2190915 for 8 weeks led to nume-
rical increases in mean change from baseline in trough
FEV1 at all doses, although none of these achieved sta-
tistical significance compared with placebo. A repeated
measures sensitivity analysis of the primary endpoint sug-
gested nominal statistical significance for GSK2190915
30 mg compared with placebo. Improvements were ob-
served in mean day-time symptom scores and mean day-
time SABA use for GSK2190915 30 mg versus placebo.
Figure 3 Sensitivity analysis of primary efficacy endpoint. Repeated measures analysis of change from baseline in trough FEV1 (L).
LS = least squares.
Figure 2 Primary efficacy endpoint. Plot of adjusted mean change from baseline in trough FEV1 at Week 8 and summary of statistical analysis.
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Figure 4 Dose–response plot of urinary LTE4. Ratio of mean change from baseline in urinary LTE4. Error bars represent 95% confidence
interval. LS = least squares.
Follows et al. Respiratory Research 2013, 14:54 Page 8 of 10
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GSK2190915 doses greater than 30 mg. The results ob-
tained in this study suggest that a GSK2190915 dose of
10 mg QD may be sub-optimal and furthermore suggest
that the FEV1 dose–response across the range investigated
(30–300 mg) was markedly flat. This was in contrast to
the plasma GSK2190915 concentrations that showed
increases with dose, and the urinary LTE4 levels that
decreased in a dose/GSK2190915 plasma concentration-
dependent manner. These pharmacokinetic and phar-
macodynamic observations were associated with high
inter-subject variability but were comparable to previ-
ously reported clinical studies [18].
The results reported in this study population sug-







N = 100 N = 99 N = 100 N =
n (%) n (%) n (%) n (
Any event 20 (20) 25 (25) 20 (20) 20
Headache 3 (3) 7 (7) 2 (2) 4
Nasopharyngitis 5 (5) 6 (6) 3 (3) 2
Cough 1 (1) 2 (2) 2 (2) 2
Nausea 1 (1) 2 (2) 1 (1) 1
Oropharyngeal pain 1 (1) 1 (1) 0 2
Back pain 0 1 (1) 2 (2) 2
QD Once-daily, FP Fluticasone propionate, BID Twice-daily.improvement on efficacy endpoints beyond those achieved
with cysLT receptor antagonism. However, this requires
further evaluation in specifically designed clinical trials. In
patients with severe asthma, where neutrophil inflamma-
tion plays a significant role in disease pathology, zileuton
has demonstrated improvements in lung function. Al-
though zileuton is the only LT synthesis inhibitor currently
available, its use has been limited by the need to monitor
hepatic enzyme levels and the high frequency of dosing
[16]. The findings from the current study indicate that
GSK2190915 could play a similar role to zileuton in terms
of its anti-LT production activity.
Urinary LTE4 levels decreased in a manner dependent
on GSK2190915 dose/GSK2190915 plasma concentration,











100 N = 101 N = 400 N = 103 N = 97
%) n (%) n (%) n (%) n (%)
(20) 24 (24) 89 (22) 25 (24) 24 (25)
(4) 4 (4) 17 (4) 9 (9) 9 (9)
(2) 5 (5) 16 (4) 5 (5) 5 (5)
(2) 2 (2) 8 (2) 3 (3) 1 (1)
(1) 3 (3) 7 (2) 1 (<1) 0
(2) 3 (3) 6 (2) 1 (<1) 1 (1)
(2) 1 (<1) 6 (2) 0 2 (2)
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GSK2190915 achieved 50% of maximum estimated in-
hibition of urinary LTE4 at a plasma concentration of
33 ng/mL, which is comparable to the value estimated
from earlier studies in healthy subjects (unpublished ob-
servations). However, reduced LTE4 was only associated
with small and non-statistically significant changes in
FEV1 from baseline. Thus, the measures of efficacy of the
present study failed to demonstrate a dose–response for
GSK2190915 on FEV1 even though the pharmacokinetic
data confirmed that an increase in drug exposure was as-
sociated with a dose-dependent decrease in the levels of
urinary LTE4.
Previous dose-ranging studies with anti-LT agents have
also shown poor relationships between urinary LTE4
concentrations and changes in FEV1 [20-22]. A study of
MK-0633, a 5-LO inhibitor, showed that inhibition of
urinary LTE4 of approximately 90% was associated with
a relatively modest change in FEV1 from baseline: 0.20 L
compared with 0.13 L for placebo in change from base-
line over the last 4 weeks of a 6-week treatment period
[21]. Zileuton led to significant increases in FEV1 after
treatment for 4 weeks (change from baseline: 0.32 L;
95% CI: 0.16, 0.48) but the levels of inhibition of urinary
LTE4 achieved were only 39% [22]. Therefore, the results
obtained in our study where inhibition of urinary LTE4
was associated with a small change from baseline in FEV1
(0.13 L for placebo and 0.18–0.23 L for GSK2190915) are
consistent with previous studies and support the hypothe-
sis that changes in LTE4 and FEV1 may not always be
highly correlated.
GSK2190915 was well-tolerated and there were no dif-
ferences between treatment groups in the frequency of
adverse events. Previous studies of zileuton and MK-
0633 suggest that these molecules may have less than
optimal safety and tolerability profiles as liver abnormali-
ties were identified [16,21]. In one study with MK-0633, a
planned extension to the study was terminated prema-
turely and the patients discontinued because of apparent
dose-related increases in alanine aminotransferase and as-
partate aminotransferase levels [21]. No such abnormal-
ities were observed in the current study.
As the original protocol allowed recruitment of both
male and female subjects, 56 males received at least one
dose of study medication. However, interim histopatho-
logical assessments of the male reproductive tract from
toxicology studies in rats, which were reported during
the conduct of the study, revealed testicular toxicity at
high exposure levels of GSK2190915. In a proportion
of the rats receiving the maximum feasible dose of
GSK2190915 (1000 mg/kg/day), testicular atrophy and
hypospermia in the epididymides were observed. The
reasons behind this finding were unclear at the time
and, therefore, it was decided to withdraw all males andonly recruit female subjects for the remainder of the
study. Although the study population was predominantly
female (92%), the results obtained in the study appear ap-
plicable to both genders as, generally, no gender-specific
results have been described in asthma treatment.
There is no clear reason that can explain why subjects
in the placebo group demonstrated such a high response
in the primary and secondary efficacy endpoints. Al-
though there were improvements within active treat-
ment groups, the placebo response may have limited the
opportunity for demonstrating significant changes in the
efficacy endpoints for active treatments relative to pla-
cebo. It is possible that, as the study population was
comprised of subjects with relatively mild asthma con-
trolled with a SABA, some subjects improved spontan-
eously and others are likely to have benefited from the
frequent contact with clinical staff and the greater atten-
tion received, which may be particularly relevant in a
mild asthmatic population.
It could be questioned why no statistically signifi-
cant difference between GSK2190915 and placebo was
achieved for the primary efficacy endpoint, particu-
larly as the outcome measure defined was the most
appropriate for a dose range study in asthma. The ob-
served response to FP, the positive control, indicated that
the enrolled population was capable of improvement in
terms of their lung function response. Furthermore, the
study was well designed, incorporated a relatively wide
dose range and active comparator and placebo arms were
included in the design. It seems to be the case that there
are areas in which the design of a randomised trial may re-
sult in gaps in the evidence they collect [23]. In particular,
randomised trials include tightly controlled and well-
characterised populations, tend to be limited in the num-
ber of outcomes evaluated and are relatively short in
duration [23]. For chronic conditions such as asthma,
concerns exist regarding the external validity of the data
gathered in randomised trials and the ability to extrapolate
these data to the heterogeneous patient population treated
in everyday clinical practice.
Conclusions
In subjects with persistent asthma, efficacy was demons-
trated for GSK2190915 30 mg compared with placebo in
mean day-time symptom scores and mean day-time
SABA use. No additional improvement on efficacy end-
points was gained by administration of GSK2190915
doses greater than 30 mg. GSK2190915 was associated
with a clear and dose-dependent reduction in urinary
LTE4. However, this did not translate into a statistically
significant improvement in mean trough FEV1 at Week
8 compared with placebo, although the presence of a
notable placebo response may have hindered the asses-
sment of the response to active treatment. The effect of
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points was comparable with montelukast but less than
low dose FP. GSK2190915 was generally safe and well-
tolerated. The GSK2190915 30 mg dose appears to be
the most appropriate for study in future clinical trials.
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